Dr. Jonathan Moore joined Dartmouth General Hospital in 2022. He completed his undergraduate degree, medical school, and urology residency training through Dalhousie University. He went on to join the Mayo Clinic in Phoenix, Arizona where he completed his Endourology and Laparoscopic/Robotic Fellowship.
Dr. Moore worked as an Assistant Professor in the Department of Urologic Surgery at UC Davis in Sacramento, California, before joining Dartmouth General. He focuses clinically on the comprehensive medical and surgical treatment of urological conditions and has a particular interest in patients with recurrent kidney stones, acute kidney stone attacks and Benign Prostatic Hyperplasia (BPH).
While in Fellowship, Dr. Moore’s clinic was one of the first centers to have the MOSES 2.0 Holmium Laser and they conducted one of the first randomized trials using the laser for the HoLEP procedure.
The Dartmouth General Hospital Foundation helped bring the HoLEP (Holmium Laser Enucleation of the Prostate) to Dartmouth General Hospital – the first hospital in Atlantic Canada to offer the procedure.
Dr. Moore is leading a major initiative to change the approach to BPH and deliver the next level of treatment for prostate patients with the latest in treatment technology, the MOSES 2.0 Holmium Laser.
BPH is extremely prevalent. 70% of men aged 60-69 have it and 80% of those over age 70 have some form of BPH. Laser is a superior treatment for patients with BPH.
The current standard and the Holmium laser currently being used is effective for kidney stone treatment but the next level up – the MOSES 2.0 Holmium Laser – will truly transform treatment.
The MOSES Holmium Laser facilitates better tissue separation, which results in better hemostasis. It is ultimately a faster, more efficient procedure with less bleeding.
Using this technology compared to a standard Holmium laser showed reduced operative times by a third, even for experts. It also reduces risk of bleeding and overall is a safer and more efficient procedure.
MOSES Holmium Laser technology is considered a platinum standard for BPH treatment. There are two key improvements: one, the ability to do the procedure with a same day discharge, and two, to do the procedure with a same day catheter removal.
In his experience with the MOSES Holmium Laser, Dr. Moore found the treatment very safe, with 90% of patients able to go home the same day and 85% who were able to go home without a catheter. This changes the BPH treatment paradigm – having an outpatient procedure without hospital costs and no increased risk of complications.
As a result, cost effectiveness of MOSES procedures for BPH versus standard treatment results in a cost savings of $840 USD per patient because the patient is home sooner. This is the most cost-effective procedure for any BPH patient – based on the durability of procedure, and the quality of life that follows. This is a more robust treatment for society and the healthcare system because it will increase access, will reduce wait times, it will reduce the risk of bleeding and patients can most often go home without a catheter.
With a successful campaign to acquire the MOSES Holmium Laser, Dartmouth General Hospital will be the first hospital in Atlantic Canada to have this technology. This is truly state of the art equipment available in only a handful of centers in Canada. The MOSES laser will be a game changer for BPH and urology patients in Nova Scotia and beyond.
The Dartmouth General Hospital Foundation aims to complete fundraising for the MOSES Holmium Laser this spring. You can read more and take action to help bring this next-generation technology to Nova Scotia here.
Other points:
- The marked difference in patient comfort and safety has led some patients from Atlantic Canada to seek care in Ontario, Quebec, or the US where this minimally invasive, less painful, and safer procedure is available.
- DGH recently acquired the Thulium Laser, used for ureteric and kidney stone management. This both diagnostic and therapeutic procedure allows for minimally invasive stone management without breaking the skin barrier.
- With both the Thulium and Holmium lasers, DGH is well-positioned to become a provincial and Atlantic Canadian leader in laser technology procedures
